| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
ABC34 is the inactive analog of the AIG1 inhibitor, JJH260. AIG1 is an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs), which are signaling lipids involved in metabolism. ABC34 does not inhibit the fluorophosphonate reactivity or the FAHFA hydrolytic activity of AIG1. It serves as a negative control to ensure that the effects seen with JJH260 are on-target. ABC34 demonstrates an IC50 greater than 25 uM for the inhibition of 9-PAHSA (a specific FAHFA).
|
|---|---|
| ln Vitro |
In vitro, ABC34 is characterized by its lack of activity against its primary intended target, AIG1. Unlike the active compound JJH260, ABC34 does not inhibit the hydrolysis of FAHFAs by AIG1. It is used as a negative control in assays to rule out any non-specific effects of the compound scaffold or the formulation. It may show weak activity against other serine hydrolases, such as ABHD6 and PPT122, but its primary function is as an inactive control. No significant in vivo activity is expected for ABC34 due to its design as an inactive control probe. Its primary use is to establish the target-specificity of its active counterpart, JJH260, in in vivo experiments. Any effects seen with ABC34 would be considered off-target and would help delineate the true pharmacology of AIG1 inhibition.
|
| Enzyme Assay |
To confirm its inactivity as a control, cell-free activity-based protein profiling (ABPP) is used. Mouse brain membrane proteomes or recombinant AIG1 are incubated with a fluorophosphonate (FP)-rhodamine probe, which labels active serine hydrolases, with or without pre-incubation with ABC34 (e.g., 1-50 uM). The samples are then run on SDS-PAGE gels, and the fluorescently labeled proteins are visualized. A reduction in the fluorescent signal of AIG1 in the presence of ABC34 would indicate inhibition; its absence confirms it is an inactive control.
|
| Cell Assay |
For cellular assays, ABC34 is used at the same concentration and duration as the active compound JJH260. Cells are treated with ABC34 (or JJH260), and then specific endpoints such as FAHFA hydrolysis or downstream signaling are measured. Any effect produced by ABC34 is considered non-specific, and the true biological effect is calculated by subtracting the effect of ABC34 from that of JJH260.
|
| Animal Protocol |
Dosing protocols for ABC34 mirror those of the active compound JJH260 to serve as a true control. In animal studies, ABC34 would be administered via intraperitoneal injection at the same dose and in the same vehicle as the active compound. For example, mice would be injected with JJH260 (20 mg/kg) or ABC34 (20 mg/kg) and then challenged with an inflammatory agent. Tissues would then be collected to measure AIG1 activity or FAHFA levels. The ABC34-treated group establishes the baseline of any vehicle-related or off-target effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ABC34 is not its primary research focus. As a control compound, its structure is designed to be closely analogous to JJH260, and it is therefore assumed to have similar pharmacokinetic properties (absorption, distribution, metabolism, excretion). This allows researchers to attribute any differences in biological activity to target engagement rather than differential compound exposure. This is a key feature of a high-quality control probe.
|
| Toxicity/Toxicokinetics |
Published toxicology data for ABC34 is limited. As an inactive control compound, it is not expected to have significant toxicity at the doses used for the active probe JJH260. In cell-based assays, its primary purpose is to have no effect, and it is typically non-toxic at experimental concentrations. Standard safety precautions for handling chemical reagents should still be followed.
|
| References | |
| Additional Infomation |
ABC34 is a research-grade chemical tool and is not approved for clinical use. Its sole purpose is to serve as a negative control in experiments involving the AIG1 inhibitor JJH260. Its use is critical for rigorous pharmacological validation of AIG1 as a drug target. The compound should be stored as a powder at -20degC, protected from light and moisture. For research use only.
|
| Molecular Formula |
C31H33N5O6
|
|---|---|
| Molecular Weight |
571.62
|
| Exact Mass |
571.243
|
| CAS # |
1831135-56-8
|
| PubChem CID |
118525588
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
42
|
| Complexity |
938
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)N2CCN(CC2)C(=O)ON3C(=O)C4CN(CCN4C3=O)CC5=CC=C(C=C5)OC6=CC=CC=C6
|
| InChi Key |
JJXNIRULKJQOCI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H33N5O6/c1-40-25-13-9-24(10-14-25)33-16-18-34(19-17-33)31(39)42-36-29(37)28-22-32(15-20-35(28)30(36)38)21-23-7-11-27(12-8-23)41-26-5-3-2-4-6-26/h2-14,28H,15-22H2,1H3
|
| Chemical Name |
[1,3-dioxo-7-[(4-phenoxyphenyl)methyl]-5,6,8,8a-tetrahydroimidazo[1,5-a]pyrazin-2-yl] 4-(4-methoxyphenyl)piperazine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7494 mL | 8.7471 mL | 17.4941 mL | |
| 5 mM | 0.3499 mL | 1.7494 mL | 3.4988 mL | |
| 10 mM | 0.1749 mL | 0.8747 mL | 1.7494 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
